WuXi NextCode’s move to split its China business from operations in the U.S. and Europe seems like the best path forward for both entities, as each faces tightening regulations that restrict the flow of genomic...

GV-incubated Rome joins a growing cadre of companies targeting repeat biology, with plans to suppress repeat DNA-induced innate immune responses to treat autoimmune disorders and activate the same pathways for cancer. Rome Therapeutics Inc. launched...

A newly created global head of partnering role at Roche (SIX:ROG; OTCQX:RHHBY) is set to combine the pharma’s partnering functions for the first time since it completed its acquisition of Genentech Inc. James Sabry, head...

Lodo Therapeutics Corp. (New York, N.Y.) and the Genentech Inc. unit of Roche (SIX:ROG; OTCQB:RHHBY) partnered to discover compounds with Lodo's Metagenomics Technology Platform against multiple undisclosed targets chosen by Genentech. The collaboration could potentially...

Lodo Therapeutics Corp. (New York, N.Y.) and the Genentech Inc. unit of Roche (SIX:ROG; OTCQB:RHHBY) partnered to discover compounds with Lodo's Metagenomics Technology Platform against multiple undisclosed targets chosen by Genentech. The collaboration could potentially...

After presiding over rapid growth in the global effort to diagnose and treat rare diseases over the past six years, the International Rare Diseases Research Consortium (IRDiRC) announced three new goals, one of which is...

The debate about the value of genome-wide association studies (GWAS) took a new twist with a Cell publication showing complex traits such as height and schizophrenia are controlled by broad, interconnected swaths of the genome...

The central thesis in the increasingly hot field of neoantigens is to pick mutations from patient tumors and turn them into personalized immunotherapies. While companies are staking out their space by defining how they will...

With the first collaborative, multidrug trial in a blood cancer, The Leukemia & Lymphoma Society aims to dramatically alter the 40-year-old diagnosis and treatment paradigm in first-line acute myelogenous leukemia, and to create a virtuous...